drugset / Trial / NCT04967521
SARC041: Study of Abemaciclib Versus Placebo in Patients with Advanced Dedifferentiated Liposarcoma
Phase 3
Active not recruiting
108 enrolled
Sarcoma Alliance for Research through Collaboration
Eli Lilly and Company · collab
RandomizedCrossoverTriple-blindTreatment
Summary
This is a Phase 3 randomized double-blind study of abemaciclib versus placebo. Patients with progression of disease will cross over to open label abemaciclib.
Timeline
- Start
- 2021-11-11
- Primary completion
- 2025-12
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abemaciclib | Small molecule | 200 mg | Oral |